Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
198
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Celldex Therapeutics Inc. market cap is $2.15B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Celldex Therapeutics Inc. 52 week high is $45.14 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Celldex Therapeutics Inc. 52 week low is $22.33 as of November 22, 2026.
Celldex Therapeutics Inc. stock price today is $27.42.
Celldex Therapeutics Inc. stock price yesterday was $27.96.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Celldex Therapeutics Inc.'s P/E ratio is -6.36.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Celldex Therapeutics Inc. P/B ratio is 3.3157.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Celldex Therapeutics Inc. 50-day moving average is $30.92.